Drug Discovery
- 1 January 2007
- book chapter
- Published by Elsevier BV
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma XenograftsCancer Research, 2004
- Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trialsBritish Journal of Cancer, 2001
- A gene expression database for the molecular pharmacology of cancerNature Genetics, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.JNCI Journal of the National Cancer Institute, 1997
- An Information-Intensive Approach to the Molecular Pharmacology of CancerScience, 1997
- Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screenDrug Development Research, 1995
- Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.Proceedings of the National Academy of Sciences of the United States of America, 1994
- A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.Molecular and Cellular Biology, 1993
- Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus.Molecular and Cellular Biology, 1986